Leo Phar­ma lines up an op­tion to buy Bridge­Bio's Pelle­Pharm and its PhI­II rare skin can­cer drug

Der­ma­tol­ogy com­pa­ny Leo Phar­ma’s vo­ra­cious ap­petite for part­ner­ships has been fu­eled with yet an­oth­er deal, this time with Bridge­Bio’s Pelle­Pharm. The Dan­ish drug­mak­er has tak­en …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER